Stage III endometrial cancer represents a challenging moment when cancer cells have spread beyond the uterus but remain confined to the pelvic area. Understanding treatment pathways and new research directions can help patients and families navigate decisions with greater confidence and clarity.

Understanding Treatment Goals for Advanced Pelvic Cancer

When endometrial cancer reaches stage III, the treatment approach becomes more complex than in earlier stages. At this point, the cancer has moved outside the uterus but has not yet traveled to distant organs like the bladder, intestines, or areas beyond the pelvis. The main goal of treatment is to remove all visible cancer, reduce the risk of it returning, and help patients maintain the best possible quality of life during and after therapy.^[2]

Stage III endometrial cancer is sometimes called locally advanced cancer because it affects nearby structures. It may have reached the outer covering of the uterus, the fallopian tubes, ovaries, vagina, or the lymph nodes in the pelvis. The stage is divided into substages—3A, 3B, and 3C—based on exactly where the cancer has spread. These distinctions matter because they influence which treatments doctors recommend and what results patients can expect.^[3]

Treatment decisions depend on several factors beyond the stage itself. Doctors consider the type of endometrial cancer cells found under the microscope, whether the cancer is fast-growing or slow-growing, the patient’s overall health and fitness for surgery, and sometimes even genetic changes within the cancer cells. Age, other medical conditions like diabetes or heart disease, and personal preferences also play important roles in shaping the treatment plan.^[15]

There are established treatments that medical societies recommend based on decades of research. At the same time, researchers are studying new therapies in clinical trials to find better ways to fight this disease. Some of these experimental approaches target specific molecules in cancer cells or harness the body’s immune system to recognize and destroy cancer. Understanding both standard care and emerging options helps patients and their care teams make informed choices.^[15]

Standard Surgical and Medical Treatments

Surgery remains the cornerstone of treatment for stage III endometrial cancer when a patient is healthy enough to undergo an operation. The goal is to remove all visible cancer tissue. This typically involves a radical hysterectomy, which means removing the uterus, cervix, both ovaries, both fallopian tubes, and often the upper part of the vagina along with surrounding tissue. Surgeons also remove lymph nodes from the pelvis to check for cancer spread and help determine the exact stage.^[3]

These operations are performed by gynecologic oncologists who specialize in this type of complex pelvic surgery. Many patients can undergo minimally invasive surgery using small incisions rather than one large opening in the abdomen. Techniques like laparoscopy or robotic-assisted surgery often lead to faster recovery, less pain after surgery, and fewer wound problems compared to traditional open surgery. However, not every patient is a candidate for minimally invasive approaches, and the choice depends on the extent of disease and the surgeon’s assessment.^[13]

Some women cannot have surgery due to other serious health problems, advanced age, or because the cancer is too difficult to remove completely. In these situations, doctors may recommend chemotherapy first to shrink the tumor, followed by surgery if the cancer responds well. Other patients may receive radiation therapy alone or combined with chemotherapy as their primary treatment instead of surgery.^[3]

Because stage III endometrial cancer has a high risk of returning after surgery, additional treatment is almost always recommended. This is called adjuvant therapy—treatment given after surgery to kill any remaining cancer cells that cannot be seen. The most common approach combines external beam radiation therapy with chemotherapy, followed by additional cycles of chemotherapy alone. This combination has been shown to improve survival compared to either treatment by itself.^[12]

External beam radiation directs high-energy rays at the pelvis from outside the body to destroy cancer cells in the area where the tumor was removed. Treatments are usually given five days a week for several weeks. Some patients also receive internal radiation called brachytherapy, where a radiation source is placed inside the vagina for a short time to deliver a high dose directly to tissues at risk.^[15]

Chemotherapy uses drugs that travel through the bloodstream to reach cancer cells anywhere in the body. For endometrial cancer, doctors typically use combinations of drugs given through an intravenous line. Common chemotherapy medicines include carboplatin paired with paclitaxel. These drugs work by damaging the DNA inside rapidly dividing cancer cells or interfering with their ability to grow and multiply. Treatment is given in cycles—usually once every three weeks—for a total of about six cycles, though the exact duration depends on how well the patient tolerates the drugs and how the cancer responds.^[12]

Chemotherapy can cause side effects because it affects not only cancer cells but also some normal cells that divide quickly, like those in the digestive tract, hair follicles, and bone marrow. Common side effects include nausea, fatigue, hair loss, increased risk of infections due to low white blood cell counts, and numbness or tingling in the hands and feet (a condition called peripheral neuropathy). Most side effects are temporary and improve after treatment ends, though some may persist. Doctors can prescribe supportive medications to help manage nausea and other symptoms during chemotherapy.^[12]

Radiation therapy can also cause side effects, particularly affecting the area being treated. These may include skin irritation similar to sunburn, diarrhea, bladder irritation causing frequent urination, fatigue, and narrowing or scarring of the vagina over time. Patients are usually advised to use vaginal dilators after radiation to prevent this narrowing, which can affect sexual function. Most radiation side effects gradually improve in the months following treatment, though some can be long-lasting.^[15]

For patients who cannot tolerate chemotherapy and radiation, hormone therapy may be an option in selected cases. This approach uses medications that block the effects of estrogen on cancer cells or lower estrogen levels in the body. Hormone therapy is typically reserved for cancers that test positive for hormone receptors and is used when other treatments are not possible. It tends to cause fewer immediate side effects than chemotherapy but is generally less effective for stage III disease.^[3]

Emerging Therapies Being Tested in Clinical Trials

Research into new treatments for stage III endometrial cancer is advancing rapidly, with several promising approaches now being tested in clinical trials. These studies evaluate whether new drugs or combinations are safe and effective before they become widely available. Clinical trials are conducted in phases, each designed to answer specific questions about a treatment.

Phase I trials focus primarily on safety. Researchers determine the appropriate dose of a new drug and identify potential side effects. These studies usually involve small numbers of patients who have already tried standard treatments. Phase II trials examine whether the new treatment shows signs of working against the cancer—for example, whether tumors shrink or stop growing. Phase III trials compare the new treatment directly to current standard care in larger groups of patients to see if it works better, has fewer side effects, or improves survival.^[15]

One of the most exciting developments in endometrial cancer treatment involves immunotherapy. These drugs work by helping the patient’s own immune system recognize and attack cancer cells. Normally, cancer cells can hide from the immune system by using certain signals that tell immune cells to leave them alone. Immunotherapy drugs block these hiding signals, allowing immune cells to do their job.

Some endometrial cancers have specific genetic changes that make them particularly responsive to immunotherapy. For example, cancers with mismatch repair deficiency or high levels of microsatellite instability often respond well to drugs called checkpoint inhibitors. These medications target proteins like PD-1 or PD-L1 on the surface of immune cells or cancer cells. Clinical trials have tested immunotherapy combined with chemotherapy for advanced or recurrent endometrial cancer, with some studies showing promising results including tumor shrinkage and improved survival in certain patient groups.^[15]

Immunotherapy can cause unique side effects because it activates the immune system broadly. These may include fatigue, skin rash, diarrhea, and inflammation of organs like the lungs, liver, or thyroid gland. Most side effects are manageable with medications that calm down the immune response, but they require careful monitoring by doctors experienced with these treatments.

Targeted therapy represents another important area of research. These drugs are designed to attack specific molecules or pathways that cancer cells need to grow and survive. Unlike chemotherapy, which affects many types of rapidly dividing cells, targeted therapies aim to be more precise. For endometrial cancer, researchers are studying drugs that block signals telling cancer cells to multiply, drugs that cut off the blood supply tumors need to grow, and drugs that target specific genetic mutations found in some endometrial cancers.

Some clinical trials are testing combinations of immunotherapy with targeted therapy. The idea is that using two different approaches together might work better than either one alone. Early results from some of these studies have shown encouraging response rates, meaning a meaningful percentage of patients experienced tumor shrinkage. However, these treatments are still being studied and are not yet part of routine care outside of clinical trials.^[15]

Gene therapy and personalized medicine approaches are also being explored. Scientists can now analyze the genetic makeup of a patient’s specific tumor to identify unique characteristics. This information might reveal which treatments are most likely to work for that individual cancer. Some trials use this genetic information to match patients with experimental drugs targeting the specific abnormalities found in their tumors.

Clinical trials for stage III endometrial cancer are being conducted at major cancer centers across the United States, Europe, and other regions. Eligibility for trials depends on many factors including the exact stage and type of cancer, previous treatments received, overall health, and the specific requirements of each study. Patients interested in clinical trials should discuss this option with their oncologist, who can help identify appropriate studies and facilitate enrollment.^[15]

Most common treatment methods

• Surgery
  • Radical hysterectomy removing the uterus, cervix, ovaries, fallopian tubes, upper vagina, and surrounding tissue
  • Pelvic lymph node removal to check for cancer spread
  • Minimally invasive techniques including laparoscopy and robotic-assisted surgery when appropriate
  • Performed by specialized gynecologic oncologists
• Radiation therapy
  • External beam radiation directed at the pelvis to destroy cancer cells
  • Internal radiation (brachytherapy) delivered inside the vagina
  • Usually given five days per week for several weeks
  • Often combined with chemotherapy for better results
• Chemotherapy
  • Systemic treatment using drugs like carboplatin and paclitaxel
  • Delivered through intravenous infusion in cycles, typically every three weeks
  • Usually given for about six cycles after surgery
  • Often combined with radiation therapy for high-risk stage III disease
• Immunotherapy
  • Checkpoint inhibitors that help the immune system attack cancer cells
  • Particularly effective for cancers with mismatch repair deficiency
  • May be combined with chemotherapy in clinical trials
  • Still being studied for stage III endometrial cancer
• Targeted therapy
  • Drugs designed to attack specific molecules in cancer cells
  • Agents that block tumor growth signals or blood vessel formation
  • Often combined with immunotherapy in research studies
  • Matched to specific genetic changes in individual tumors
• Hormone therapy
  • Medications that block estrogen effects on cancer cells
  • Used when patients cannot tolerate chemotherapy or radiation
  • Reserved for hormone receptor-positive cancers
  • Generally causes fewer immediate side effects than chemotherapy